Fernández-Cisnal Agustín, Valero Ernesto, García-Blas Sergio, Pernias Vicente, Pozo Adela, Carratalá Arturo, González Jessika, Noceda José, Miñana Gema, Núñez Julio, Sanchis Juan
Cardiology Department, University Clinic Hospital of València, Instituto de Investigación Sanitaria (INCLIVA), University of València, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), 46010 València, Spain.
Clinical Biochemistry Department, University Clinic Hospital of València, Instituto de Investigación Sanitaria (INCLIVA), 46010 València, Spain.
J Clin Med. 2021 Apr 20;10(8):1784. doi: 10.3390/jcm10081784.
Decision-making is challenging in patients with chest pain and normal high-sensitivity cardiac troponin T (hs-cTnT; <99th percentile; <14 ng/L) at hospital arrival. Most of these patients might be discharged early. We investigated clinical data and hs-cTnT concentrations for risk stratification. This is a retrospective study including 4476 consecutive patients presenting to the emergency department with chest pain and first normal hs-cTnT. The primary endpoint was one-year death or acute myocardial infarction, and the secondary endpoint added urgent revascularization. The number of primary and secondary endpoints was 173 (3.9%) and 252 (5.6%). Mean hs-cTnT concentrations were 6.9 ± 2.5 ng/L. Undetectable (<5 ng/L) hs-cTnT ( = 1847, 41%) had optimal negative predictive value (99.1%) but suboptimal sensitivity (90.2%) and discrimination accuracy (AUC = 0.664) for the primary endpoint. Multivariable analysis was used to identify the predictive clinical variables. The clinical model showed good discrimination accuracy (AUC = 0.810). The addition of undetectable hs-cTnT (≥ or <5 ng/L; HR, hazard ratio = 3.80; 95% CI, confidence interval 2.27-6.35; = 0.00001) outperformed the clinical model alone (AUC = 0.836, = 0.002 compared to the clinical model). Measurable hs-cTnT concentrations (between detection limit and 99th percentile; per 0.1 ng/L, HR = 1.13; CI 1.06-1.20; = 0.0001) provided further predictive information (AUC = 0.844; = 0.05 compared to the clinical plus undetectable hs-cTnT model). The results were reproducible for the secondary endpoint and 30-day events. Clinical assessment, undetectable hs-cTnT and measurable hs-cTnT concentrations must be considered for decision-making after a single negative hs-cTnT result in patients presenting to the emergency department with acute chest pain.
对于入院时胸痛且高敏心肌肌钙蛋白T(hs-cTnT;<第99百分位数;<14 ng/L)正常的患者,决策具有挑战性。这些患者中的大多数可能会提前出院。我们研究了临床数据和hs-cTnT浓度以进行风险分层。这是一项回顾性研究,纳入了4476例连续因胸痛就诊于急诊科且首次hs-cTnT正常的患者。主要终点是一年内心脏死亡或急性心肌梗死,次要终点增加了紧急血运重建。主要终点和次要终点的例数分别为173例(3.9%)和252例(5.6%)。hs-cTnT的平均浓度为6.9±2.5 ng/L。不可测(<5 ng/L)的hs-cTnT(n = 1847,41%)对主要终点具有最佳的阴性预测价值(99.1%),但敏感性(90.2%)和鉴别准确性(AUC = 0.664)欠佳。采用多变量分析来确定预测性临床变量。临床模型显示出良好的鉴别准确性(AUC = 0.810)。加入不可测的hs-cTnT(≥或<5 ng/L;HR,风险比 = 3.80;95% CI,置信区间2.27 - 6.35;P = 0.00001)的模型表现优于单独的临床模型(AUC = 0.836,与临床模型相比P = 0.002)。可测的hs-cTnT浓度(在检测限至第99百分位数之间;每0.1 ng/L,HR = 1.13;CI 1.06 - 1.20;P = 0.0001)提供了进一步的预测信息(AUC = 0.844;与临床加不可测hs-cTnT模型相比P = 0.05)。对于次要终点和30天事件,结果具有可重复性。对于因急性胸痛就诊于急诊科且hs-cTnT单次检测结果为阴性的患者,决策时必须考虑临床评估、不可测的hs-cTnT和可测的hs-cTnT浓度。